★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Hims & Hers Health, Inc. (HIMS) Moat Analysis
Hims & Hers Health, Inc.
HIMS · New York Stock Exchange
Partial score covering 83% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Hims & Hers sells cash-pay telehealth and pharmacy subscriptions. Q2 2026 revenue rose 38% to $753.2 million, with 2.9 million subscribers. U.S. revenue grew 16% and represented 82.6% of sales. Rest of World revenue reached 17.4% after the Eucalyptus acquisition contributed for about one month. The clearest advantage is operating control across the app, provider coordination, and licensed pharmacy fulfillment. That can lower service costs, but it is not a strong moat. Customers can cancel with little friction, competitors can copy subscriptions, and the company does not disclose enough cohort retention evidence to support durable brand power. Gross margin fell to 64%, while regulation of compounded GLP-1 drugs remains a major risk.
Primary segment
United States Platform
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-08-23
Segments
United States Platform
Direct-to-consumer telehealth + subscription pharmacy (cash-pay) for lifestyle and chronic conditions
Revenue
82.6%
Structure
Competitive
Pricing
weak
Share
—
Peers
Rest of World Platform
Direct-to-consumer digital health and pharmacy/fulfillment platform outside the United States
Revenue
17.4%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
United States Platform
Direct-to-consumer telehealth + subscription pharmacy (cash-pay) for lifestyle and chronic conditions
Revenue share uses Q2 2026 United States revenue of $621.8 million divided by total revenue of $753.2 million. U.S. revenue grew 16% year over year. The result does not prove durable retention because the company does not disclose cohort churn or customer acquisition payback by geography.
Operational Excellence
Supply
Operational Excellence
Strength
Durability
Confidence
Evidence
End-to-end operating capability (platform + provider network coordination + fulfillment) can reduce cost-to-serve and improve the customer experience versus a more fragmented model reliant on third parties.
Operational Excellence moat: definition, examples, and stocks
Erosion risks
- Operational disruption (fulfillment errors, delays, quality failures)
- FDA restrictions or enforcement affecting compounded GLP-1 drugs and related marketing
- Scale advantage competed away if large incumbents match execution
Leading indicators
- Gross margin trend (especially as mix shifts)
- Delivery time SLAs and pharmacy fulfillment error rates
- Customer support contact rate per order/subscriber
Counterarguments
- Operational playbooks can be copied; fulfillment scale can be purchased via 3P logistics/pharmacy networks
- Incumbent retailers and Amazon can out-scale on logistics and supply chain
Rest of World Platform
Direct-to-consumer digital health and pharmacy/fulfillment platform outside the United States
Revenue share uses Q2 2026 Rest of World revenue of $131.4 million divided by total revenue of $753.2 million. The quarter includes about one month of Eucalyptus after the June 2 closing, so the 17-fold year-over-year increase is not an organic comparison. The filing does not support a durable international moat yet.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
drug delivery and supply chain oversight
Supports a supply-side advantage claim: integrated fulfillment capabilities can improve delivery experience and reduce reliance on third-party pharmacy contracts.
two licensed 503A pharmacies and two pharmacies licensed by the UK General Pharmaceutical Council
Owned/licensed facilities support operational control over fulfillment and service levels.
Risks & Indicators
Erosion risks
- Operational disruption (fulfillment errors, delays, quality failures)
- FDA restrictions or enforcement affecting compounded GLP-1 drugs and related marketing
- Scale advantage competed away if large incumbents match execution
Leading indicators
- Gross margin trend (especially as mix shifts)
- Delivery time SLAs and pharmacy fulfillment error rates
- Customer support contact rate per order/subscriber
- Cost of revenue per shipment
Research HIMS elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.